Efficacy and Safety of treatment with Levofloxacin for Community-acquired Pneumonia

Not Applicable

• Conditions: Community-acquired pneumonia in adults

• Registration Number: JPRN-UMIN000008677
• Lead Sponsor: Second Division, Department of Internal Medicine, Hamamatsu university school of medicine

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2012-08-14
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 300

Inclusion Criteria

Not provided

Exclusion Criteria

1.Patients who took respiratory quinolones for current pneumonia. 2.Patients who are prohibited to take levofloxacin. 3.Patients with liver dysfunction AST:more than three times the upper limit of normal ALT:more than three times the upper limit of normal T-bil:more than three times the upper limit of normal 4.Patients witg renal dysfunction (Cre is over than 3.0mg/dl, or Ccr is less than 30 mL/min/1.73m2) 5.Patients who has disease of central nervous system and expected spasm. 6.Patient whom conducting of the examination doctor judged inappropriate.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Clinical effectiveness at seven days after the end of treatment.

Secondary Outcome Measures

Name	Time	Method
Clinical and bacteriological effectiveness at the end of treatment. mortality, hospitalization, adverse event.